Atlas Trials

Altimmune, Inc.

19 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Altimmune, Inc.

RecordFirmDate
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) (NCT07009860)Altimmune, Inc.2025-06-16
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight (NCT06987513)Altimmune, Inc.2025-05-15
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (NCT05989711)Altimmune, Inc.2023-07-27
Efficacy and Safety of ALT-801 in the Treatment of Obesity (NCT05295875)Altimmune, Inc.2022-03-31
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) (NCT05292911)Altimmune, Inc.2022-03-09
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM) (NCT05134662)Altimmune, Inc.2022-02-01
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) (NCT05006885)Altimmune, Inc.2021-09-30
Pemvidutide (ALT-801) DDI Study in Healthy Volunteers (NCT04972396)Altimmune, Inc.2021-09-15
Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study) (NCT04679909)Altimmune, Inc.2021-02-25
HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) (NCT04684914)Altimmune, Inc.2020-12-26
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability (NCT04561245)Altimmune, Inc.2020-11-10
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) (NCT04442230)Altimmune, Inc.2020-10-10
NasoShield in Healthy Adults to Study Safety and Immunogenicity (NCT04415749)Altimmune, Inc.2020-06-15
Study of the Safety and Immunogenicity of NasoVAX Extension (NCT03760549)Altimmune, Inc.2019-01-21
NasoShield Study of Safety and Immunogenicity (NCT03352466)Altimmune, Inc.2018-01-18
Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX (NCT03232567)Altimmune, Inc.2017-09-18

Track Altimmune, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.